TRUE RELIGION APPAREL [TRLG] was left tattered and threadbare after tumbling 27.3% to close at $15.46 (basically the same price it had at the beginning of 2006) after reporting third quarter results that fell below expectations. Sales for the third quarter were $42.9 million, up 22.6% over third quarter sales for 2005. Third quarter earnings were $8.2 million ($0.35 per share) up 6.3% over the earnings for the same period last year, however the consensus estimate had been for earnings to come in at $0.44 per share. The company’s revenue guidance for the full-year was revised to $138 to $140, well below the consensus estimate of $149.98 million but still implying a growth rate of 35% to 36% over 2005, and earnings guidance for the full-year was revised to $1.11 to $1.12 per share. Three downgrades didn’t help: CIBC World Markets from “Sector Outperform” to “Sector Perform,” Friedman Billings from “Outperform” to “Market Perform,” and Wedbush Morgan from “Buy” to “Hold.” Our sense is that the selling pressure was too extreme and that this is probably a very good time to find faith in TRUE RELIGION. Watch for the full 10-Q filing to get a better sense of how they are doing internationally.
HOLLIS EDEN PHARMACEUTICALS INC [HEPH] dropped 18.7% closing at $5.97 on the news that it would be raising $26 million through the sale of common stock to both new and existing institutional investors. The sale involves 4 million shares at $6.50 per share, with four-year warrants to purchase an additional 800,000 shares at an exercise price of $8.75. At the beginning of November, there were about 25 million shares outstanding. While any price significantly below $6.50 is probably an opportunity, development-stage pharmaceutical companies are very speculative and we would rather have more insight into how the proceeds of the sale are going to be used before assuming any risk in this area.
HOSPIRA INC [HSP] fell 11.9% closing at $33.30 after reporting third quarter revenues that came in well below expectations, although earnings after adjusted for special charges were in line with expectations. Third quarter revenues of $646.6 million actually fell 1.5% from the third quarter 2005, and with a P/E ratio of 24.6 we see no current opportunities.
UTSTARCOM INC [UTSI] slid 8.4% closing at $9.37 after announcing that it would be delaying the release of its third quarter results until it completes a review of its historical stock option award practices. Currently the company does not expect the review to be completed before the extended filing deadline of November 16th. Given the losses that the company has been piling up over the past two years, we do not see this as a buying opportunity.
HUMAN GENOME SCIENCES INC [HGSI] sank 8.1% closing at $12.71 after reporting a bigger than expected loss in the third quarter. The company reported a loss of $0.46 per share, compared to a loss of $0.42 per share for the same period last year. Adding back in $0.05 per share for stock based compensation, the loss would have been $0.41 per share which is only a penny below the consensus estimate of $0.40 per share.
While the long-term debt of $750.9 million is a serious concern, the increase in long-term debt of about $240 million in the second quarter is associated with the sale and leaseback arrangement involving its facilities space. By selling the facility the company netted about $219 million (not $225,000 as footnoted in the 10-Q) and since it has a repurchase option, the company has chosen to add $225 million to the long-term debt, which seems prudent. We suppose the downgrade by Wachovia from “Outperform” to “Market Perform” was not helpful. There are apparently 8 new drugs in the pipeline, with Albuferon™ for the treatment of hepatitis C, which it is co-developing with Novartis, being the leading candidate. The company expects to initiate Phase 3 trials before the end of 2006.
SOTHEBYS HOLDINGS INC [BID] dropped 7.5% closing at $34.49 apparently only on the news of downgrades by JMP Securities from “Strong Buy” to “Market Outperform” and by Wedbush Morgan from “Buy” to “Hold.” We don’t see much risk here and probably a reasonable entry point with a modest dividend yield. Future growth probably comes from the international bidders and new auction technology.
PLAYBOY ENTERPRISES INC [PLA] hopped up 7.1% closing at $12.15 after announcing that although third quarter earnings were worse than last year, the company was still in the black, with earnings of $0.03 per share versus a consensus estimate of a loss of $0.03 per share. While the company is hopeful regarding advertising revenues both online and with the magazine, we are skeptical and do not see a long opportunity.
VERASUN ENERGY CORP [VSE] up another sunny 9% to close at $20.40
STEMCELLS INC [STEM] surged up 10.4% to close at $3.39 undoubtedly following the big wins for stem cell research in the midterm elections.
ARRAY BIOPHARMA INC [ARRY] rose 11.8% closing at $11.93 on the announcement that preliminary trials of an enzyme inhibitor (AZD6244) being developed by the company have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Phase II clinical trials have been initiated in patients with skin, pancreatic, lung and colon cancers.
TRIMERIS INC [TRMS] shot up 22.7% closing at $9.73 following a swing to profitability in the third quarter. The company reported third quarter revenues of $9.7 million, which more than doubled its Q3 revenue for 2005 of $4.6 million. Earnings were $0.16 per share compared with a loss of ($0.15) per share for the same period last year. The results were driven by the global sales of the FUZEON, the first in a new class of anti-HIV drugs called fusion inhibitors. Analysts are skeptical about future growth potential given concerns about side effect reactions and competition, but the company is working on a next-generation version of the drug and looking for FDA approval of a needle-less means of administering the drug. So long as they stay in the black, this remains speculative but attractive.
NEUROMETRIX INC [NURO] recovered from most of the damage done on October 24th, jumping 23.9% to close at $18.69 after announcing strong third quarter results. The company reported earnings of $0.18 per share which easily beat the consensus estimate of $0.10 per share. While the P/E is getting high again at about 50, the third quarter revenue growth of about 68% still points to some more upside potential. See also our previous post:
GREENFIELD ONLINE INC [SRVY] blossomed 26.3% closing at $12.86 after announcing a very strong third quarter and raising its annual guidance. Much of the success seems to be coming from the company’s Ciao comparison shopping site in Europe, which grew net revenues by 93% over the third quarter of 2005. Revenue for the entire company for the quarter was $24.875 million up 7.5% over the third quarter of 2005. The company now projects full-year revenue for fiscal 2006 to be in the range of $93 to $97 million, about 4% higher than previous guidance, with margins in the range of 73% to 75%, which is also about 4% higher than previous guidance. On the negative side, we were not impressed by the year-over-year, 0.7% growth in the North American Internet Survey Solutions segment. The Ciao Internet Survey Solutions segment was also rather weak with growth of only 1.9%. Given the strong growth in the Ciao comparison shopping segment (from $2.6 million in Q3 2005 to $5.1 million in Q3 2006), the company will be faced with some hard decisions. Maintaining an unbiased survey sample AND a comparison shopping service at the same time is not a walk in the park! Be very careful here!
Daily Sector Performance Chart
At first blush it appears that Pharmaceuticals did not take a big hit following the landslide win by the Democrats. However, when you look at the breakdown of the Pharmaceutical segment, it is pretty clear that the traditional big pharma stocks were almost uniformly in negative territory for the day. However, the drops were reasonably modest, ranging from ELI LILLY & CO [LLY] with a drop of 0.88% to MERCK & CO [MRK] with a drop of 3.4% and a median drop in “big pharma” of about 1.6%.
Across the entire SI Universe, the average gain for the day was 0.63% with 65.6% of the members posting positive returns for the day. The outliers on Wednesday were Alternative Energy (up 2.2%), Tobacco (up 2.1%) and Travel (up 2.4%).
